Osimertinib Improves Survival in Frontline EGFR+ NSCLC

[ad_1]

Jose Baselga, MD

José Baselga, MD

Frontline osimertinib (Tagrisso) considerably enhanced all round survival (OS) compared with erlotinib (Tarceva) or gefitinib (Iressa) in sufferers with EGFR-constructive regional sophisticated or metastatic non–small cell lung cancer (NSCLC), according to outcomes from the phase III FLAURA trial.1

T790M–positive NSCLC whose illness progressed on or soon after EGFR TKI therapy.&#13
&#13


References

    &#13

  1. Tagrisso considerably improves all round survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-compact cell lung cancer. AstraZeneca. Posted August 9, 2019. Accessed August 9, 2019. https://bit.ly/2ZGF7gZ.
  2. &#13

  3. Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs typical of care (SoC) EGFR-TKI as very first-line therapy in sufferers (pts) with EGFRm sophisticated NSCLC: FLAURA. Presented at: 2017 ESMO Congress Madrid, Spain September 9-12, 2017. Abstract LBA2_PR.
  4. &#13


… to study the complete story

[ad_2]

Latest posts